Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?
2019 ◽
Vol 25
(1)
◽
pp. 57-63
◽
Keyword(s):
The emergence of biologic therapies has revolutionized the management of inflammatory bowel disease (IBD) by halting disease progression, increasing remission rates and improving long-term clinical outcomes. Despite these well-described benefits, many patients are reluctant to commence therapy due to drug safety concerns. Adverse events can be detected at each stage of drug development and during the post-marketing period. In this article, we review how to best assess the safety parameters of new IBD medications, from the earliest stage of development to population-based registries, with a focus on the special populations often excluded from the evaluation process.
2012 ◽
Vol 26
(8)
◽
pp. 525-531
◽
2020 ◽
Vol 14
(Supplement_1)
◽
pp. S297-S298
Keyword(s):
Keyword(s):